BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28258917)

  • 1. Spectrum of fungal infection in head and neck cancer patients on chemoradiotherapy.
    Singh GK; Capoor MR; Nair D; Bhowmik KT
    J Egypt Natl Canc Inst; 2017 Mar; 29(1):33-37. PubMed ID: 28258917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of changes in the oral fungal flora of patients on radiotherapy for head and neck malignancies and their correlation with funguria and fungemia.
    Raj S; Sharma D; Mate P; Capoor MR; Bhowmik KT
    Indian J Cancer; 2017; 54(1):39-42. PubMed ID: 29199660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003-2007).
    Raghuram A; Restrepo A; Safadjou S; Cooley J; Orloff M; Hardy D; Butler S; Koval CE
    Liver Transpl; 2012 Sep; 18(9):1100-9. PubMed ID: 22577087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signs, symptoms and the prevalence of fungi detected from the oral cavity and pharynx of radiotherapy subjects with head and neck tumors, and their susceptibility to chemotherapeutics.
    Kurnatowski P; Moqbil S; Kaczmarczyk D
    Ann Parasitol; 2014; 60(3):207-13. PubMed ID: 25281818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer.
    Yokota T; Hamauchi S; Yoshida Y; Yurikusa T; Suzuki M; Yamashita A; Ogawa H; Onoe T; Mori K; Onitsuka T
    Support Care Cancer; 2018 Sep; 26(9):3241-3248. PubMed ID: 29627862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.
    Belazi M; Velegraki A; Koussidou-Eremondi T; Andreadis D; Hini S; Arsenis G; Eliopoulou C; Destouni E; Antoniades D
    Oral Microbiol Immunol; 2004 Dec; 19(6):347-51. PubMed ID: 15491459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral infections caused by yeasts in patients with head and neck cancer undergoing radiotherapy. Identification of the yeasts and evaluation of their antifungal susceptibility.
    Bulacio L; Paz M; Ramadán S; Ramos L; Pairoba C; Sortino M; Escovich L; López C
    J Mycol Med; 2012 Dec; 22(4):348-53. PubMed ID: 23518170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oropharyngeal candidiasis in head and neck cancer patients in Iran: Species identification, antifungal susceptibility and pathogenic characterization.
    Jahanshiri Z; Manifar S; Moosa H; Asghari-Paskiabi F; Mahmoodzadeh H; Shams-Ghahfarokhi M; Razzaghi-Abyaneh M
    J Mycol Med; 2018 Jun; 28(2):361-366. PubMed ID: 29602636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An underestimated pitfall of oral candidiasis in head and neck cancer patients undergoing radiotherapy: an observation study.
    Chitapanarux I; Wongsrita S; Sripan P; Kongsupapsiri P; Phakoetsuk P; Chachvarat S; Kittidachanan K
    BMC Oral Health; 2021 Jul; 21(1):353. PubMed ID: 34271901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
    Yokota T; Ogawa T; Takahashi S; Okami K; Fujii T; Tanaka K; Iwae S; Ota I; Ueda T; Monden N; Matsuura K; Kojima H; Ueda S; Sasaki K; Fujimoto Y; Hasegawa Y; Beppu T; Nishimori H; Hirano S; Naka Y; Matsushima Y; Fujii M; Tahara M
    BMC Cancer; 2017 May; 17(1):314. PubMed ID: 28476132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy.
    Nicolatou-Galitis O; Velegraki A; Sotiropoulou-Lontou A; Dardoufas K; Kouloulias V; Kyprianou K; Kolitsi G; Skarleas C; Pissakas G; Papanicolaou VS; Kouvaris J
    Support Care Cancer; 2006 Jan; 14(1):44-51. PubMed ID: 15947956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between cumulative radiation dose and the incidence of severe oral mucositis in head and neck cancers during radiotherapy.
    Sunaga T; Nagatani A; Fujii N; Hashimoto T; Watanabe T; Sasaki T
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1317. PubMed ID: 33295153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Can the prophylactic treatment of mycotic mucositis improve the time of performing radiotherapy in head and neck tumors?].
    Gava A; Ferrarese F; Tonetto V; Coghetto F; Marazzato G; Zorat PL
    Radiol Med; 1996 Apr; 91(4):452-5. PubMed ID: 8643858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy.
    Yokota T; Tachibana H; Konishi T; Yurikusa T; Hamauchi S; Sakai K; Nishikawa M; Suzuki M; Naganawa Y; Hagihara T; Tsumaki H; Kubo T; Sato M; Taguri M; Morita S; Eguchi T; Kubota K; Zenda S
    Support Care Cancer; 2016 Jul; 24(7):3029-36. PubMed ID: 26887378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study.
    Gouvêa de Lima A; Villar RC; de Castro G; Antequera R; Gil E; Rosalmeida MC; Federico MH; Snitcovsky IM
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):270-5. PubMed ID: 21163585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The timing of the appearance of oral mucositis induced by concurrent chemoradiotherapy with S-1 for head and neck cancer].
    Yonekita H; Takase H; Ogata K; Futagami K; Nomoto S; Yoshimitsu K; Nakagawa T; Tokunaga S
    Gan To Kagaku Ryoho; 2014 Dec; 41(13):2571-5. PubMed ID: 25596050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confounding factors associated with oral mucositis assessment in patients receiving chemoradiotherapy for head and neck cancer.
    Chung YL; Pui NNM
    Support Care Cancer; 2017 Sep; 25(9):2743-2751. PubMed ID: 28353040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.